223 related articles for article (PubMed ID: 25146487)
1. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.
Schoepfer AM; Bortolotti M; Pittet V; Mottet C; Gonvers JJ; Reich O; Fournier N; Vader JP; Burnand B; Michetti P; Froehlich F
Aliment Pharmacol Ther; 2014 Oct; 40(8):930-7. PubMed ID: 25146487
[TBL] [Abstract][Full Text] [Related]
2. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
3. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
Castillo-Regalado E; Ríos R; Aràjol C; Gely C; Márquez L; Calafat M; González-Muñoza C; Cañete F; Mesonero F; Guardiola J; Garcia-Planella E; Mañosa M; Domènech E
Gastroenterol Hepatol; 2023 Mar; 46(3):164-170. PubMed ID: 36179946
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminosalicylates and effects on renal function in patients with Crohn's disease.
de Jong DJ; Tielen J; Habraken CM; Wetzels JF; Naber AH
Inflamm Bowel Dis; 2005 Nov; 11(11):972-6. PubMed ID: 16239842
[TBL] [Abstract][Full Text] [Related]
5. 5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study.
Duricova D; Pedersen N; Elkjaer M; Jensen JK; Munkholm P
J Crohns Colitis; 2010 Nov; 4(5):575-81. PubMed ID: 21122562
[TBL] [Abstract][Full Text] [Related]
6. Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.
Ma C; Ascoytia C; McCarrier KP; Martin M; Feagan BG; Jairath V
Dig Dis Sci; 2018 Oct; 63(10):2555-2563. PubMed ID: 29959726
[TBL] [Abstract][Full Text] [Related]
7. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
Picetti D; Kim J; Zhu W; Sandborn WJ; Jairath V; Singh S
Dig Dis Sci; 2022 Jul; 67(7):3115-3123. PubMed ID: 34797442
[TBL] [Abstract][Full Text] [Related]
8. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
[TBL] [Abstract][Full Text] [Related]
10. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
Godat S; Fournier N; Safroneeva E; Juillerat P; Nydegger A; Straumann A; Vavricka S; Biedermann L; Greuter T; Fraga M; Abdelrahman K; Hahnloser D; Sauter B; Rogler G; Michetti P; Schoepfer AM;
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):612-620. PubMed ID: 29384798
[TBL] [Abstract][Full Text] [Related]
11. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease.
de Franchis R; Omodei P; Ranzi T; Brignola C; Rocca R; Prada A; Pera A; Vecchi M; Del Piano M; Ferrara A; Belloli C; Piodi L; Framarin L; Astegiano M; Riccioli FA; Meucci G
Aliment Pharmacol Ther; 1997 Oct; 11(5):845-52. PubMed ID: 9354191
[TBL] [Abstract][Full Text] [Related]
12. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
13. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
14. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease.
Ma C; Dutton SJ; Cipriano LE; Singh S; Parker CE; Nguyen TM; Guizzetti L; Gregor JC; Chande N; Hindryckx P; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2018 Jul; 48(2):114-126. PubMed ID: 29851091
[TBL] [Abstract][Full Text] [Related]
16. [5-aminosalicylic acid for induction of remission or clinical response in Crohn's disease--a survey of a Cochrane review].
Bjerrum JT; Munck LK; Nielsen OH
Ugeskr Laeger; 2011 Aug; 173(35):2110-3. PubMed ID: 21884660
[TBL] [Abstract][Full Text] [Related]
17. The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.
Burisch J; Bergemalm D; Halfvarson J; Domislovic V; Krznaric Z; Goldis A; Dahlerup JF; Oksanen P; Collin P; de Castro L; Hernandez V; Turcan S; Belousova E; D'Incà R; Sartini A; Valpiani D; Giannotta M; Misra R; Arebi N; Duricova D; Bortlik M; Gatt K; Ellul P; Pedersen N; Kjeldsen J; Andersen KW; Andersen V; Katsanos KH; Christodoulou DK; Sebastian S; Barros L; Magro F; Midjord JM; Nielsen KR; Salupere R; Kievit HA; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Kaimakliotis IP; Schwartz D; Odes S; Lakatos L; Lakatos PL; Langholz E; Munkholm P;
United European Gastroenterol J; 2020 Oct; 8(8):949-960. PubMed ID: 32715989
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of circulating platelet derived microparticles in Crohn's disease patients.
Tziatzios G; Polymeros D; Spathis A; Triantafyllou M; Gkolfakis P; Karakitsos P; Dimitriadis G; Triantafyllou K
Scand J Gastroenterol; 2016 Oct; 51(10):1184-92. PubMed ID: 27191369
[TBL] [Abstract][Full Text] [Related]
19. Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease.
Cury DB; Moss AC
Inflamm Bowel Dis; 2010 Aug; 16(8):1393-6. PubMed ID: 19998457
[TBL] [Abstract][Full Text] [Related]
20. Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort.
Orlando A; Mocciaro F; Renna S; Scimeca D; Rispo A; Lia Scribano M; Testa A; Aratari A; Bossa F; Tambasco R; Angelucci E; Onali S; Cappello M; Fries W; D'Incà R; Martinato M; Castiglione F; Papi C; Annese V; Gionchetti P; Rizzello F; Vernia P; Biancone L; Kohn A; Cottone M
J Crohns Colitis; 2014 Oct; 8(10):1217-21. PubMed ID: 24630485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
